Shopping Cart
- Remove All
 
Your shopping cart is currently empty
Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia.

| Pack Size | Price | Availability | Quantity | 
|---|---|---|---|
| 1 mg | $71 | 1-2 weeks | 
| Description | Zosuquidar (RS 33295-198) is a potent P-glycoprotein inhibitor with antitumor activity, inhibits tumor growth, significantly inhibits PD-L1 expression by triggering its autophagic degradation, and is used in the study of acute myeloid leukemia.  | 
| In vitro | Zosuquidar (0.3 μM, treated for 48 hours) enhances the cytotoxic effect of DNR (P-glycoprotein substrate) in P-glycoprotein-active cell lines. [2] Zosuquidar (5-16 μM, treated for 72 hours) alone exhibited strong cytotoxicity in drug-sensitive cell lines and multidrug resistant (MDR) cell lines. [1]  | 
| In vivo | Intraperitoneal injection of 30, 10, 3, or 1 mg/kg Zosuquidar once daily for 5 days significantly prolonged subject survival. [1] Intraperitoneal injection of 30 mg/kg Zosuquidar once daily for 5 days observed a significant potentiation when combined with adriamycin (Doxorubicin). [1]  | 
| Synonyms | RS33295-198, RS 33295-198, LY-335979, LY335979 | 
| Molecular Weight | 527.6 | 
| Formula | C32H31F2N3O2 | 
| Cas No. | 167354-41-8 | 
| Smiles | FC1(F)[C@]2([C@@]1(C=3C([C@@H](C=4C2=CC=CC4)N5CCN(C[C@H](COC=6C7=C(C=CC6)N=CC=C7)O)CC5)=CC=CC3)[H])[H] | 
| Relative Density. | 1.36 g/cm3 | 
| Color | White | 
| Appearance | Solid | 
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (151.63 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (9.48 mM), Sonication is recommended.  Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.